爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

rottapharm ltd - oestradiol hemihydrate - transdermal patch - 100 microgram/day

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

rottapharm ltd - oestradiol hemihydrate - transdermal patch - 50 microgram/day

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

rottapharm ltd - oestradiol hemihydrate - transdermal patch - 100 microgram/day

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

rottapharm ltd - oestradiol hemihydrate - transdermal patch - 25 microgram/day

欧盟 - 英文 - EMA (European Medicines Agency)

almirall, s.a. - tirbanibulin - keratosis, actinic - antibiotics and chemotherapeutics for dermatological use - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - testosterone - transdermal patch - 2.5 mg/day

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - testosterone - transdermal patch - 2.5 mg/day

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - oxybutynin, quantity: 36 mg - drug delivery system, transdermal - excipient ingredients: triacetin; ethyl acetate; povidone; 2-ethylhexyl acrylate; hexamethylene glycol dimethacrylate; cyclohexane; dilauroyl peroxide; isopropyl alcohol; dimeticonol; methicone; dibutyltin diacetate; heptane; toluene; aminoethylaminopropyl trimethoxysilane; polyethylene terephthalate; ethylene/vinyl acetate copolymer - oxytrol is indicated for the treatment of overactive bladder with symptoms of urinary frequency, urgency or incontinence or any combination of these symptoms.

美国 - 英文 - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - marlissa® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. marlissa® (levonorgestrel and ethinyl estradiol tablets) is contraindicated in females who are known to have the following conditions:                                                               marlissa® (mĀr-lis-sĂ)                              (levonorgestrel and ethinyl estradiol tablets, usp 0.15 mg/0.03 mg) important information about taking marlissa® (levonorgestrel and ethinyl estradiol tablets) before you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets): when should i start taking marlissa® (levonorgestrel and ethinyl estradiol tablets)? if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you have not used a hormonal birth control method before: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from another birth control pill: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and previously used a vaginal ring: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and previously used a transdermal patch: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from a progestin-only method such as an implant or injection: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from an intrauterine device or system (iud or ius): keep a calendar to track your period: if this is the first time you are taking birth control pills, read, “when should i start taking marlissa® (levonorgestrel and ethinyl estradiol tablets)? ” above. follow these instructions for either a sunday start or a day 1 start . instructions for using your marlissa® (levonorgestrel and ethinyl estradiol tablets) pill dispenser: sunday start: you will use a sunday start if your healthcare provider told you to take your first pill on a sunday. day 1 start: you will use a day 1 start if your doctor told you to take your first pill (day 1) on the first day of your period . what should i do if i miss any marlissa® (levonorgestrel and ethinyl estradiol tablets) pills? if you miss 1 pill in weeks 1, 2, or 3, follow these steps: if you miss 2 pills in week 1 or week 2 of your pack, follow these steps: if you miss 2 pills in a row in week 3, or you miss 3 or more pills in a row during weeks 1, 2, or 3 of the pack, follow these steps: if you have any questions or are unsure about the information in this leaflet, call your healthcare provider. this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured by: glenmark pharmaceuticals limited colvale-bardez, goa 403513, india manufactured for: glenmark pharmaceuticals inc., usa mahwah, nj 07430 questions? 1 (888) 721-7115 www.glenmarkpharma-us.com june 2022

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.32 mg (equivalent: estradiol, qty 2.25 mg) - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; isopropyl palmitate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (see section 4.4 special warnings and precautions for use and section 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.